Dr. Kabos’ interest is in translating preclinical findings into novel treatments for patients with breast cancer. The Kabos lab focuses on the role of breast cancer stem cells and tumor microenvironment in treatment resistance.
BardiaA, KaklamaniV, WilksS, WeiseA, RichardsD, HarbW, OsborneC, WesolowskiR, KaruturiM, Conkling P, BagleyRG,WangY, ConlanMG, KabosP. A phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader, in ER-positive, HER2-negative advanced breast cancer. Journal of Clinical Oncology 2021 (Jan 29:JCO2002272. doi: 10.1200/JCO.20.02272. Online ahead of print. PMID: 33513026
Stoen E, Kagihara J, Shagisultanova E, Fisher CM, Nicklawsky A, Kabos P, Borges VF, Diamond JR.Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval. Breast Cancer Res Treat. 2021 Feb 24. doi: 10.1007/s10549-021-06132-8. Online ahead of print. PMID: 33625615
Schreiber AR, Kagihara JA, Weiss JA, Nicklawsky A, Gao D, Borges VF, Kabos P, Diamond JR. Clinical Outcomes for patients with metastatic breast cancer treated with immunotherapy agents in phase I clinical trials. Front Oncol. 2021 Mar 17. PMID: 33816286
Smyth LM, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, Jhaveri K, Varga A, Wong A, Schram AM, Ambrose H, Carr TH, de Bruin EC, Salinas-Souza C, Foxley A, Hauser J, Lindemann JPO, Maudsley R, McEwen R, Moschetta M, Nikolaou M, Schiavon G, Razavi P, Banerji U, Baselga J, Hyman DM, Chandarlapaty S. Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. NPJ Breast Cancer. 2021 April 16; 7(1):44. PMID: 33863913
Rao S, Han AL, Zukowski A, Kopin E, Sartorius CA, Peter Kabos, Srinivas Ramachandran. Mapping transcription factor-nucleosome dynamics from plasma cfDNA. BioRxiv. 2021 April 15 (https://doi.org/10.1101/2021.04.14.439883) Co-senior author.